Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1439-1444, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahashi, M.
Right arrow Articles by Inoue, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, M.
Right arrow Articles by Inoue, T.

Clinical Chemistry, Vol 42, 1439-1444, Copyright © 1996 by American Association for Clinical Chemistry

Direct quantification of pentosidine in urine and serum by HPLC with column switching

M Takahashi, H Hoshino, K Kushida, K Kawana and T Inoue
Department of Orthopedic Surgery, Hamamatsu University School of Medicine, Japan.

Concentrations of pentosidine, an advanced glycation end product, are increased in aging, diabetes mellitus, and uremia. Using HPLC with column switching, we developed a direct method of measuring pentosidine in urine and serum. We inject the sample directly onto a gel-filtration precolumn, select ("heart-cut") the eluate fraction containing pentosidine, and introduce this fraction into a reversed-phased column by use of a switching valve. The recovery rate of the complete method was 97.7-99.9%. The intraassay CV was 5.7%, and the interassay CV was 5.8%. The calibration curve showed significant linearity (r = 0.998, P = 0.0001). We examined urinary concentrations of pentosidine in 12 diabetic patients (mean +/- SD, 8.7 +/- 2.3 micromol/mol of creatinine), 32 patients with chronic renal failure (CRF; 36.1 +/- 39.0), 19 osteoporotic patients (7.9 +/- 5.3), and 29 healthy control subjects (5.2 +/- 2.3). In CRF, urinary pentosidine in the patients undergoing hemodialysis was significantly higher than in CRF patients not being treated by hemodialysis (mean, 58.1 vs 18.2; P <0.001). Also, concentrations of urinary and serum pentosidine were significantly correlated (r = 0.797, P = 0.0011). Because this method does not require pretreatment of samples, it is convenient and useful for measuring urinary and serum pentosidine.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. V. Schwartz, P. Garnero, T. A. Hillier, D. E. Sellmeyer, E. S. Strotmeyer, K. R. Feingold, H. E. Resnick, F. A. Tylavsky, D. M. Black, S. R. Cummings, et al.
Pentosidine and Increased Fracture Risk in Older Adults with Type 2 Diabetes
J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2380 - 2386.
[Abstract] [Full Text] [PDF]

Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
M. Takahashi, M. Oikawa, and A. Nagano
Effect of Age and Menopause on Serum Concentrations of Pentosidine, an Advanced Glycation End Product
J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2000; 55(3): 137M - 140.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.